CA-4948 Phase 1 Promising To Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes
Reading Time: 3 minutes Curis Inc has reported their CA-4948 treatment has shown an overall tumor decrease of >20% from baseline. Downstream pharmacodynamic markers of IRAK4 are being actively evaluated and Molecular characteristics including … Read More